Nonprescription Drugs Advisory Committee (NDAC)

in joint session with the

Advisory Committee for Reproductive Heath Drugs (ACRHD)

December 16, 2003

CONSULTANTS AND GUESTS

SGE Consultants (voting)

Abby B. Berenson, M.D. Professor, Obstetrics/Gynecology & Pediatrics Director, UTMB Center for interdisciplinary Research in Women's Health Chief, Division of Pediatric and Adolescent Gynecology The University of Texas Medical Branch Galveston, Texas 77555-0587

Michael F. Greene, M.D. Department of Obstetrics and Gynecology Massachusetts General Hospital 55 Fruit Street, Founders 4 Boston, Massachusetts 02114 Geri D. Hewitt, M.D. Department of Obstetrics and Gynecology Ohio State University 4053 Dublin-Granville Dublin, Ohio 43017

James Trussell, Ph.D. Associate Dean John Foster Dulles Professor in International Affairs Professor of Economics and Public Affairs Director, Office of Population Research Woodrow Wilson School, Princeton University Princeton, New Jersey 08544

Acting Industry Representative (non-voting)

Michael C. Alfano, DMD, PhD Dean, College of Dentistry New York University 345 East 24th Street New York, New York, 10010

~~

FDA Participants at the Table (non-voting)

Steven K. Galson, M.D., M.P.H. Acting Director Center for Drug Evaluation and Research

Sandra Kweder, M.D. Deputy Director Office of New Drugs, CDER

Jonca Bull, M.D. Director Office of Drug Evaluation V Julie Beitz, M.D. Deputy Director Office of Drug Evaluation III

Donna Griebel, M.D. Deputy Director Division of Reproductive and Urologic Drug Products

Curtis Rosebraugh, M.D., M.P.H. Deputy Director Division of Over-the-Counter Drug Products